Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an oral antiplatelet medication that reversibly inhibits the P2Y12 receptor on platelets, thereby preventing platelet activation and aggregation.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** For the reduction of thrombotic cardiovascular events in patients with ACS, including unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI), managed medically or with percutaneous coronary intervention (PCI).
* **Myocardial Infarction (MI) with History:** In patients with a history of MI at least one year prior, ticagrelor is indicated to reduce the rate of cardiovascular death, MI, and stroke, following completion of at least 12 months of dual antiplatelet therapy.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* In patients with ACS who are treated with PCI, a dose of 60 mg twice daily may be considered after the first year for patients who have completed 12 months of treatment with 90 mg twice daily and are not at high risk for bleeding or major adverse events.
* **History of MI (at least 1 year prior):** 60 mg orally twice daily.
## Pediatric Dosing
Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
No dose adjustments are typically required based on age, gender, or renal/hepatic impairment. However, caution and careful consideration of bleeding risk are warranted in patients with hepatic impairment.
## Contraindications
* Active bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect, including spontaneous or trauma-related bleeding (e.g., epistaxis, bruising, gastrointestinal bleeding, genitourinary bleeding).
* **Dyspnea:** Transient, often mild and self-limiting, but can be significant.
* **Bradycardia:** May occur, especially in patients taking other medications that cause bradycardia.
* **Hyperuricemia:** And possible gout.
* **Increased serum creatinine.**
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors may increase ticagrelor exposure. Conversely, coadministration with strong CYP3A4 inducers may decrease ticagrelor exposure.
* **CYP3A4 Substrates (especially statins):** Ticagrelor can increase concentrations of certain CYP3A4 substrates, such as simvastatin and atorvastatin, potentially increasing the risk of myopathy. Dosing adjustments of these concomitant medications may be necessary.
* **Other Antiplatelets and Anticoagulants:** Increased risk of bleeding. Avoid coadministration with potent P2Y12 inhibitors (e.g., clopidogrel, prasugrel) and consider risk/benefit for other anticoagulants.
* **Proton Pump Inhibitors (PPIs):** Some data suggest that PPIs may reduce the efficacy of ticagrelor. While not a formal contraindication, consider the timing of administration or alternative agents if possible.
## Monitoring
* **Clinical signs of bleeding:** Monitor for any signs or symptoms of bleeding.
* **Platelet Function:** While not routinely recommended, platelet function tests may be considered in specific clinical scenarios to assess response or guide therapy.
* **Renal and Hepatic Function:** Periodic monitoring may be appropriate, especially in patients with pre-existing impairment or those taking interacting medications.
* **EKG:** For evidence of bradycardia.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor but works via a reversible mechanism, unlike clopidogrel and prasugrel.
* The dose of 60 mg twice daily is a lower maintenance dose for long-term therapy in select ACS patients after 1 year and for patients with a history of MI.
* Always administer a loading dose of aspirin (per local protocol) with ticagrelor. Aspirin maintenance dose should not exceed 100 mg daily.
* Patients experiencing significant dyspnea should be evaluated for underlying causes, but ticagrelor-induced dyspnea may be transient.
* Discontinuation of ticagrelor can increase the risk of thrombotic events. Assess the risk of bleeding versus the risk of thrombosis when considering discontinuation.
***
*This information is intended as a quick reference and does not substitute for comprehensive clinical judgment or consultation of the full prescribing information. Always verify current dosing and safety information with the official product monograph or other authoritative sources.*
